Pembrolizumab represents a new standard first-line treatment option for PD-L1–expressing advanced/metastatic NSCLC, according to KEYNOTE-042 investigators.
Original Article: Pembrolizumab Bests Chemotherapy in PD-L1 Expressing NSCLC